Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$1.98
+0.5%
$2.24
$1.89
$4.34
$590.88M0.462.89 million shs2.12 million shs
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$3.45
+7.1%
$3.27
$2.71
$4.73
$660.77M1.5996,927 shs1.12 million shs
AC Immune SA stock logo
ACIU
AC Immune
$1.69
$1.68
$1.43
$4.98
$169.69M1.62167,437 shs130,042 shs
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$2.97
+2.4%
$4.13
$2.28
$6.71
$376.76M1.851.17 million shs875,106 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+0.51%-5.26%-22.96%-32.19%-48.57%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
+7.14%+7.48%+4.86%+0.44%+4.86%
AC Immune SA stock logo
ACIU
AC Immune
0.00%-3.43%+3.05%-32.94%-52.26%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
+2.41%-8.90%-34.87%-8.62%+12.93%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.8681 of 5 stars
3.42.00.00.03.73.30.6
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
2.1866 of 5 stars
3.50.00.00.03.82.50.6
AC Immune SA stock logo
ACIU
AC Immune
2.6253 of 5 stars
3.53.00.00.02.70.81.3
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
4.1224 of 5 stars
3.31.00.04.33.83.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.75
Moderate Buy$8.33320.88% Upside
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
3.00
Buy$5.5059.42% Upside
AC Immune SA stock logo
ACIU
AC Immune
3.00
Buy$10.00491.72% Upside
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5085.19% Upside

Current Analyst Ratings Breakdown

Latest ACIU, ORGO, ABUS, and ABCL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $10.00
5/1/2025
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $12.00
4/16/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.00
4/3/2025
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/28/2025
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
3/14/2025
AC Immune SA stock logo
ACIU
AC Immune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/5/2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$4.00 ➝ $6.00
3/3/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/28/2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$23.11M25.56N/AN/A$3.97 per share0.50
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
$6.40M103.20N/AN/A$0.63 per share5.48
AC Immune SA stock logo
ACIU
AC Immune
$28.30M6.00N/AN/A$2.12 per share0.80
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$458.76M0.82$0.19 per share15.72$2.11 per share1.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.40M-$0.56N/AN/AN/A-533.32%-15.73%-12.22%8/5/2025 (Estimated)
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$72.85M-$0.41N/AN/AN/A-1,137.65%-68.18%-51.55%7/30/2025 (Estimated)
AC Immune SA stock logo
ACIU
AC Immune
-$60.41M-$0.58N/AN/AN/AN/A-28.26%-18.98%8/5/2025 (Estimated)
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$4.95M-$0.17N/AN/AN/A-1.62%-2.69%-1.63%8/14/2025 (Estimated)

Latest ACIU, ORGO, ABUS, and ABCL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million
5/8/2025Q1 2025
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million
5/8/2025Q1 2025
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
4/30/2025Q1 2025
AC Immune SA stock logo
ACIU
AC Immune
-$0.22-$0.21+$0.01-$0.21$1.99 million$1.12 million
3/27/2025Q4 2024
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
-$0.08-$0.07+$0.01-$0.07$2.20 million$1.57 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/AN/AN/AN/AN/A
AC Immune SA stock logo
ACIU
AC Immune
N/AN/AN/AN/AN/A
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
9.34
9.34
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
N/A
7.02
7.02
AC Immune SA stock logo
ACIU
AC Immune
N/A
1.86
1.86
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
0.21
3.09
2.74

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
43.79%
AC Immune SA stock logo
ACIU
AC Immune
51.36%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
49.57%

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.90%
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
20.30%
AC Immune SA stock logo
ACIU
AC Immune
4.60%
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
36.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500298.42 million212.66 millionOptionable
Arbutus Biopharma Co. stock logo
ABUS
Arbutus Biopharma
90191.53 million181.91 millionOptionable
AC Immune SA stock logo
ACIU
AC Immune
140100.41 million94.39 millionOptionable
Organogenesis Holdings Inc. stock logo
ORGO
Organogenesis
950126.85 million79.33 millionOptionable

Recent News About These Companies

CMS reviewing coverage policies for skin substitute products

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$1.98 +0.01 (+0.51%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.03 +0.05 (+2.53%)
As of 04:43 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Arbutus Biopharma stock logo

Arbutus Biopharma NASDAQ:ABUS

$3.45 +0.23 (+7.14%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.42 -0.03 (-0.87%)
As of 05/27/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

AC Immune stock logo

AC Immune NASDAQ:ACIU

$1.69 0.00 (0.00%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.72 +0.04 (+2.07%)
As of 05/27/2025 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$2.97 +0.07 (+2.41%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$3.02 +0.05 (+1.68%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.